TY - JOUR
T1 - Characterization CSMD1 in a large set of primary lung, head and neck, breast and skin cancer tissues
AU - Ma, Changqing
AU - Quesnelle, Kelly M.
AU - Sparano, Anthony
AU - Rao, Shilpa
AU - Park, Min S.
AU - Cohen, Marc A.
AU - Wang, Yan
AU - Samanta, Minu
AU - Kumar, Madhu S.
AU - Aziz, M. Usman
AU - Naylor, Tara L.
AU - Weber, Barbara L.
AU - Fakharzadeh, Steven S.
AU - Weinstein, Gregory S.
AU - Vachani, Anil
AU - Feldman, Michael D.
AU - Brose, Marcia S.
PY - 2009/5/15
Y1 - 2009/5/15
N2 - The Cub and Sushi Multiple Domains-1 (CSMD1) is a tumor suppressor gene on 8p23.2, where allelic loss is both frequent and associated with poor prognosis in head and neck squamous cell carcinoma (HNSCC). To understand the extent of CSMD1 aberrations in vivo, we characterized 184 primary tumors from the head and neck, lung, breast and skin for gene copy number and analyzed expression in our HNSCCs and lung squamous cell carcinomas (SCCs). We detected loss of CSMD1 in a large proportion of HNSCCs (50%), lung (46%) and breast cancers (55%), and to a lesser extent in cutaneous SCCs (29%) and basal cell carcinomas (BCCs, 17%) using array-based comparative genomic hybridization (aCGH). Studying the region more closely with quantitative real-time PCR (qPCR), the loss of CSMD1 increased to 80% in HNSCCs and 93% in lung SCCs. CSMD1 expression was decreased in tumors compared to adjacent benign tissue (65%, 13/20) and was likely due to gene loss in 45% of cases (9/20). We also identified truncated transcripts lacking exons due to DNA copy number loss (30%, 5/17) or aberrant splicing (24%, 4/17). We show loss of CSMD1 in primary HNSCC tissues, and document for the first time that CSMD1 is lost in breast, lung and cutaneous SCCs. We also show that deletions of CSMD1 and aberrant splicing contribute to altered CSMD1 function in vivo.
AB - The Cub and Sushi Multiple Domains-1 (CSMD1) is a tumor suppressor gene on 8p23.2, where allelic loss is both frequent and associated with poor prognosis in head and neck squamous cell carcinoma (HNSCC). To understand the extent of CSMD1 aberrations in vivo, we characterized 184 primary tumors from the head and neck, lung, breast and skin for gene copy number and analyzed expression in our HNSCCs and lung squamous cell carcinomas (SCCs). We detected loss of CSMD1 in a large proportion of HNSCCs (50%), lung (46%) and breast cancers (55%), and to a lesser extent in cutaneous SCCs (29%) and basal cell carcinomas (BCCs, 17%) using array-based comparative genomic hybridization (aCGH). Studying the region more closely with quantitative real-time PCR (qPCR), the loss of CSMD1 increased to 80% in HNSCCs and 93% in lung SCCs. CSMD1 expression was decreased in tumors compared to adjacent benign tissue (65%, 13/20) and was likely due to gene loss in 45% of cases (9/20). We also identified truncated transcripts lacking exons due to DNA copy number loss (30%, 5/17) or aberrant splicing (24%, 4/17). We show loss of CSMD1 in primary HNSCC tissues, and document for the first time that CSMD1 is lost in breast, lung and cutaneous SCCs. We also show that deletions of CSMD1 and aberrant splicing contribute to altered CSMD1 function in vivo.
KW - Breast cancer
KW - CSMD1
KW - Epithelial cancers
KW - Head and neck cancer
KW - Lung cancer
KW - Squamous cell carcinoma
KW - Tumor suppressor genes
UR - http://www.scopus.com/inward/record.url?scp=68049139551&partnerID=8YFLogxK
U2 - 10.4161/cbt.8.10.8132
DO - 10.4161/cbt.8.10.8132
M3 - Article
C2 - 19276661
AN - SCOPUS:68049139551
SN - 1538-4047
VL - 8
SP - 907
EP - 916
JO - Cancer Biology and Therapy
JF - Cancer Biology and Therapy
IS - 10
ER -